Pembrolizumab
- Generic Name
- Pembrolizumab
- Brand Names
- Keytruda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1374853-91-4
- Unique Ingredient Identifier
- DPT0O3T46P
- Background
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
- Indication
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
- Associated Conditions
- Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06572722
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 800
- Registration Number
- NCT06561386
- Locations
- 🇺🇸
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
🇺🇸Local Institution - 0369, Canton, Ohio, United States
🇧🇷Local Institution - 0382, Fortaleza, Ceará, Brazil
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 69
- Registration Number
- NCT06558799
- Locations
- 🇦🇹
Universitätsklinik f. Innere Medizin III, Salzburg, Austria
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 20
- Registration Number
- NCT06558214
- Locations
- 🇺🇸
UF Health Shands Hospital, Gainesville, Florida, United States
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 741
- Registration Number
- NCT06556563
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸Swedish Medical Center, Seattle, Washington, United States
🇺🇸UF Health Neuromedicine, Gainesville, Florida, United States
Study of XB010 in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 350
- Registration Number
- NCT06545331
- Locations
- 🇺🇸
Exelixis Clinical Site #4, Duarte, California, United States
🇺🇸Exelixis Clinical Site #3, Huntersville, North Carolina, United States
🇺🇸Exelixis Clinical Site #1, Austin, Texas, United States
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06545955
- Locations
- 🇺🇸
Ferring Investigational Site, Los Angeles, California, United States
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Microbiotica Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06540391
- Locations
- 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷CHU de Lille - Hopital Claude Huriez, Lille, France
🇫🇷Centre Leon Berard, Lyon, France
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06538012
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.